. Author manuscript; available in PMC: 2009 Mar 30.

Published in final edited form as: J Drug Issues. 2006 Jul 1;36(3):541–570. doi: 10.1177/002204260603600303

Table 3.

PHA Participation in RAP Training Program and CAG Meetings

			N	(%)
Initiated training program			130	(73.9)^a
Attended office training (Sessions 1-5)			112	(86.2)^b
Attended 2 or more partnered field sessions (“full training”)			104	(80.0)^b
Attended 10 training sessions (all possible sessions)			66	(50.8)^b
CAG meetings attended:^c
	Any meetings:		88	(78.6)^d
		1 or 2 meetings only	29	(33.0)^e
		3-5 meetings only	32	(36.4)^e
		6+ meetings	27	(30.2)^e

Percentage is based on number of participants who were recruited as PHAs (n = 176).

Percentage is based on number of participants who initiated the training program (n = 130).

Mean number of CAG meetings attended by all trained PHAs (i.e., those who attended 5 or more PHA training sessions) was 3.97 meetings (median = 3.0, SD = 4.58, range 0-21).

Percentage is based on number of PHAs eligible to participate in CAG meetings (n = 112).

Percentage is based on number of participants who attended at least one CAG meeting (n = 88).